LEKTI-6 (Peptide for neurodermatitis) - Haemopep Pharma GmbH
LEKTI, a serine proteinase inhibitor, is at this time being developed as a drug for the treatment of atopic dermatitis (neurodermatitis) in the preclinical phase. The project is run by Haemopep Pharma GmbH, an active subsidiary of Pharis Biotec GmbH since December 2006.
LEKTI, a serine proteinase inhibitor, is at this time being developed as a drug for the treatment of atopic dermatitis (neurodermatitis) in the preclinical phase. The project is run by Haemopep Pharma GmbH, an active subsidiary of Pharis Biotec GmbH since December 2006.
